Medical technology company Becton Dickinson announced on 28 March 2013 that FDA had approved the first drug in its line of prefilled generic injectables. This can only be good news for FDA who has been fighting to alleviate drug shortages in the US, most of which are due to shortages in generic sterile injectables.
- Home
 - 
                                Generics 
                                                                
News
- FDA approves generic teriparatide and levetiracetam
 - US generics launch and approval for Dr Reddy’s and Lupin
 - Five Chinese companies join UN’s MPP for Covid-19 medicines
 - South Korean companies to make generic Bridion and COVID-19 drugs
 
Research
- Japan’s drug shortage crisis: challenges and policy solutions
 - Saudi FDA drug approvals and GMP inspections: trend analysis
 - Generic medications in the Lebanese community: understanding and public perception
 - Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
 
 - 
                                Biosimilars 
                                                                
News
- FDA approves six denosumab biosimilars
 - EMA recommends approval for four biosimilars targeting three therapies
 - FDA approves first interchangeable rapid-acting insulin biosimilar, Kirsty
 - ANVISA approves ranibizumab and tocilizumab biosimilars
 
 - MORE EDITORIAL SECTIONS
 
- Search
 
                    


            
    
    
                        
                            
            
    
    
                                                                
            
    
    
                                                                
            
    
    
                                                                
            
    
    
                                                                
            
    
    
                                                        
            
    
    
                                                        
            
    
    
                                                        
            
Post your comment